October 16-19, 2024 | New York City |
Dr. Adam Cohen received his medical degree and did his internal medicine residency at the University of Pennsylvania, Philadelphia. He completed a hematology/oncology fellowship at Memorial Sloan-Kettering Cancer Center, New York, including research training in the Laboratory of Tumor Immunology under Alan Houghton, MD. He then served as faculty on the Hematology Service at Fox Chase Cancer Center, Philadelphia. Currently, he is Director of Myeloma Immunotherapy, and an Associate Professor of Medicine at the Abramson Cancer Center, University of Pennsylvania, Philadelphia.
Dr. Cohen is board certified in medical oncology and hematology and treats patients with myeloma, AL amyloidosis and related plasma cell disorders. He is a member of ASCO, ASH, and AACR. He is also a member of the Multiple Myeloma Committee, Eastern Cooperative Oncology Group, and has served on the NCCN Multiple Myeloma Guidelines Panel and the National Cancer Institute's Myeloma Steering Committee. His research interests involve novel therapeutics for plasma cell diseases, particularly vaccines, antibodies and cellular immunotherapies.